Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
FOXO4-DRI
FOXO4
Thymosin Beta-4
TMSB4X
The clearest overlap between FOXO4-DRI and Thymosin Beta-4 is that both converge around Protein interaction inhibitor. Their typical research and application settings separate fairly clearly: FOXO4-DRI is more often discussed in the realm of Aging and longevity, whereas Thymosin Beta-4 is more often associated with the realm of Musculoskeletal health, Cardiovascular health, and Dermatology and aesthetics. Both appear to work through Protein interaction inhibitor, but the functional emphasis still separates, with FOXO4-DRI leaning toward Cellular senescence clearance and Thymosin Beta-4 leaning toward Tissue repair and healing, Angiogenesis modulation, and Anti-inflammatory. FOXO4-DRI has a more synthetic design origin, while Thymosin Beta-4 is closer to natural endogenous background with FOXO4-DRI in Preclinical development and Thymosin Beta-4 in Clinical phase 2. FOXO4-DRI carries retro-inverso isomerization features, while Thymosin Beta-4 instead reflects acetylation changes.